Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0)

G. J. Ossenkoppele, D. A. Breems, G. Stuessi, Y. van Norden, M. Bargetzi, B. J. Biemond, P. A von dem Borne, Y. Chalandon, J. Cloos, D. Deeren, M. Fehr, B. T. Gjertsen, C. Graux, G. Huls, J. J.J.W. Janssen, A. Jaspers, M. Jongen-Lavrencic, E. de Jongh, S. K. Klein, M. Van der KliftM. Van Marwijk Kooy, J. Maertens, L. Michaux, M. W.M. van der Poel, A. Van Rhenen, L. Tick, P. Valk, M. C. Vekemans, W. J.F.M. van der Velden, O. de Weerdt, T. Pabst, M. Manz, B. Löwenberg, D. A. Breems, Havelange, M. C. Vekemans, I. Moors, F. van Obberg, J. A. Maertens, B. Hodossy, S. Vansteenweghen, L. Lammertijn, D. Deeren, C. Graux, A. Sonet, A. Triffet, B. T. Gjertsen, M. Bargetzi, J. Passweg, D. Heim, San Giovanni, Georg Stuessi, T. Pabst, D. Betticher, Y. Chalandon, O. Spertini, M. Gregor, U. Hess, M. Fehr, M. G. Manz, S. K. Klein, B. J. Biemond, G. J. Ossenkoppele, A. van de Loosdrecht, J. J.W.M. Janssen, J. W.J. van Esser, M. Van der Klift, R. E. Brouwer, D. Van Lammeren-Venema, M. D. Levin, L. W. Tick, M. C.J.C. Legdeur, G. Huls, E. Vellenga, M. Hoogendoorn, J. H. Veelken, P. A. von dem Borne, H. C. Schouten, O. de Weerdt, W. J.F.M. van der Velden, J. Cornelissen, M. Jongen-Lavrencic, B. Wouters, H. G.M. Raaijmakers, B. Löwenberg, J. Kuball, A. Van Rhenen, M. Van Marwijk Kooy, for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK)

Research output: Contribution to journalComment/Letter to the editorAcademic

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Original languageEnglish
JournalLeukemia
DOIs
Publication statusAccepted/In press - 1 Jan 2020

Cite this

Ossenkoppele, G. J., Breems, D. A., Stuessi, G., van Norden, Y., Bargetzi, M., Biemond, B. J., ... for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) (Accepted/In press). Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0). Leukemia. https://doi.org/10.1038/s41375-020-0994-7